Abstract
Platelet P2 receptors-P2Y1, P2Y12, and P2X1-constitute the means by which adenine nucleotides can activate platelets. Coactivation of the Gαq-coupled P2Y1 and Gαi2-coupled P2Y12 receptors is necessary for ADPmediated platelet activation, which forms the basis of using P2 antagonists as antithrombotic drugs. P2Y1 receptor antagonists inhibit platelet activation, while P2Y1 knockout mice show longer bleeding times than normal mice but few other problems; however, its ubiquitous expression in other tissues renders P2Y1 questionable as an antithrombotic target. The P2Y12 receptor is expressed nearly exclusively in platelets and brain, making it an attractive antithrombotic target. Antagonists for the P2Y12 receptor have been developed that either require metabolic activation to covalently inhibit P2Y12 and are irreversible, or simply are competitive in nature and thus reversible. Ticlopidine and clopidogrel are irreversible P2Y12 antagonists and have been repeatedly proven as clinical antithrombotic agents. In addition, a recently reported P2Y12 antagonist, CS-747, shows promise as a future antithrombotic drug. The AR-C series of compounds represent reversible P2Y12 antagonists and have been used extensively to characterize the function of P2Y12 in platelets. Clinical studies show that AR-C69931MX is as effective as clopidogrel; furthermore, the combination of AR-C69931MX (cangrelor) and clopidogrel confers greater antagonism of P2Y12 than either antagonist alone. The P2X1 receptor is a calcium channel that functions to potentiate agonist-induced platelet shape change, and its inhibition or loss has little if any effect on hemostasis. A combination of P2Y1 and P2Y12 antagonists may represent an additional course of antithrombotic treatment.
Keywords: platelets, p2x1 receptor, p2y1 receptor, p2y12 receptor, adp receptor, platelet aggregation
Current Pharmaceutical Design
Title: ADP Receptors-Targets for Developing Antithrombotic Agents
Volume: 9 Issue: 28
Author(s): Satya P. Kunapuli, Zhongren Ding, Robert T. Dorsam, Soochong Kim, Swaminathan Murugappan and Todd M. Quinton
Affiliation:
Keywords: platelets, p2x1 receptor, p2y1 receptor, p2y12 receptor, adp receptor, platelet aggregation
Abstract: Platelet P2 receptors-P2Y1, P2Y12, and P2X1-constitute the means by which adenine nucleotides can activate platelets. Coactivation of the Gαq-coupled P2Y1 and Gαi2-coupled P2Y12 receptors is necessary for ADPmediated platelet activation, which forms the basis of using P2 antagonists as antithrombotic drugs. P2Y1 receptor antagonists inhibit platelet activation, while P2Y1 knockout mice show longer bleeding times than normal mice but few other problems; however, its ubiquitous expression in other tissues renders P2Y1 questionable as an antithrombotic target. The P2Y12 receptor is expressed nearly exclusively in platelets and brain, making it an attractive antithrombotic target. Antagonists for the P2Y12 receptor have been developed that either require metabolic activation to covalently inhibit P2Y12 and are irreversible, or simply are competitive in nature and thus reversible. Ticlopidine and clopidogrel are irreversible P2Y12 antagonists and have been repeatedly proven as clinical antithrombotic agents. In addition, a recently reported P2Y12 antagonist, CS-747, shows promise as a future antithrombotic drug. The AR-C series of compounds represent reversible P2Y12 antagonists and have been used extensively to characterize the function of P2Y12 in platelets. Clinical studies show that AR-C69931MX is as effective as clopidogrel; furthermore, the combination of AR-C69931MX (cangrelor) and clopidogrel confers greater antagonism of P2Y12 than either antagonist alone. The P2X1 receptor is a calcium channel that functions to potentiate agonist-induced platelet shape change, and its inhibition or loss has little if any effect on hemostasis. A combination of P2Y1 and P2Y12 antagonists may represent an additional course of antithrombotic treatment.
Export Options
About this article
Cite this article as:
Kunapuli P. Satya, Ding Zhongren, Dorsam T. Robert, Kim Soochong, Murugappan Swaminathan and Quinton M. Todd, ADP Receptors-Targets for Developing Antithrombotic Agents, Current Pharmaceutical Design 2003; 9 (28) . https://dx.doi.org/10.2174/1381612033453947
DOI https://dx.doi.org/10.2174/1381612033453947 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Current Molecular Medicine Evaluation of in-vitro Anti Diabetic Activity of a Siddha Herbo- Mineral Drug
Current Traditional Medicine Keeping the Balance Between Proliferation and Differentiation:The Primary Cilium
Current Genomics Central Blood Pressure and Prediction of Cardiovascular Events
Current Hypertension Reviews Osteoblastic Responses to LPS, Glucose-oxidised LDL and Minocycline: Therapeutic Targets for Periodontal and Cardiometabolic Diseases
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Obesity, Diabetes and Cardiovascular Diseases in India: Public Health Challenges
Current Diabetes Reviews Emerging Approved Treatments for Idiopathic Pulmonary Fibrosis: Some Hope for Patients?
Current Respiratory Medicine Reviews Podocytes as a Target of Insulin
Current Diabetes Reviews Correlation of Urine Biomarkers: Microalbuminuria and Spot Urine Protein among Diabetic Patients. Application of Spot Urine Protein in Diabetic Kidney Disease, Nephropathy, Proteinuria Estimation, Diagnosing and Monitoring
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Hemostatic Factors and the Metabolic Syndrome
Current Vascular Pharmacology Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review
Reviews on Recent Clinical Trials High Doses of In vitro Beta-carotene, Alpha-Tocopherol and Ascorbic Acid Induce Oxidative Stress and Secretion of IL-6 in Peripheral Blood Mononuclear Cells from Healthy Donors
Current Aging Science Wound-Associated Skin Fibrosis: Mechanisms and Treatments Based on Modulating the Inflammatory Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Host Molecular Defense Mechanisms Against Chlamydophila pneumoniae and Genetic Studies of Immune-Response-Related Genes in Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Antimalarial Drugs and their Useful Therapeutic Lives: Rational Drug Design Lessons from Pleiotropic Action of Quinolines and Artemisinins
Current Drug Discovery Technologies Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Functional, Genetic and Biochemical Biomarkers of Peripheral Arterial Disease
Current Medicinal Chemistry Neutrophil to Lymphocyte (N/L) and Platelet to Lymphocyte (P/L) Ratios in Differentiating Acute Heart Failure from Respiratory Infection
Current Vascular Pharmacology